María-Pilar Martínez

Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

J. Hernández-Rivas, S. Brunet, J. Ribera, 2016, Leukemia & lymphoma.

Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.

J. Esteve, S. Mercadal, M. Tormo, 2018, Leukemia research.

Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.

L. Escoda, M. Tormo, A. Cladera, 2016, Leukemia research.

Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score

L. Pleyer, R. Greil, P. Fenaux, 2015 .

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)

L. Pleyer, R. Greil, P. Fenaux, 2018, Leukemia & lymphoma.

Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy.

S. Mercadal, M. Tormo, J. Hernández-Rivas, 2020, Clinical lymphoma, myeloma & leukemia.

Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

S. Mercadal, L. Escoda, J. Hernández-Rivas, 2017, Annals of Hematology.